Year: 2025

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with no specialized oncology oversight, demonstrating the feasibility of administering this regimen outside the hospital setting No cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) Consistent and complete B-cell depletion was observed in all patients with autoimmune disease treated with AlloNK + mAb by Day 13 of treatment, consistent with the experience for AlloNK + mAb in B-cell driven lymphoma Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) regulatory interactions to align on pivotal...

Amended filing in the Eastern District of Texas broadens Alpha Modus’s retail AI patent claims following its 2025 settlement with Kroger, covering enterprise-wide in‑store and analytics platforms involving Cooler Screens CORNELIUS, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Alpha Modus, Corp. (“Alpha Modus”), the subsidiary of Alpha Modus Holdings, Inc. (NASDAQ:AMOD), a developer and licensor of artificial intelligence–driven retail technologies, today announced that it has filed an Amended Complaint for Patent Infringement against The Kroger Co. in the U.S. District Court for the Eastern District of Texas (Case No. 2:25-cv-00923).The amended filing expands Alpha Modus’s original complaint filed in 2025 from eight to nine asserted patents, adding U.S. Patent No. 10,853,825, and the newly issued U.S. Patent No. 12,423,718, which extends...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CASA GRANDE, Ariz. and TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) —  Arizona Sonoran Copper Company Inc. (TSX:ASCU | OTCQX:ASCUF) (“ASCU” or the “Company”) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought-deal private placement basis, 22,388,100 common shares of the Company (the “Common Shares”) at a price of C$3.35 per Common Share (the “Offering Price”) for gross proceeds of C$75,000,135 (the ” Offering”). The Company has also granted the Underwriters an option to purchase up to an additional 3,358,200 Common...